RNA interference based gene therapy for neurological disease

Briefings in Functional Genomics and Proteomics

Volumn 6, Issue 1, 2007, Pages 40-49

  Jagannath, Aarti ^a   Wood, Matthew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Gene therapy; microRNA; Neurodegenerative disease; RNA interference; siRNA

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID PRECURSOR PROTEIN; CHOLINERGIC RECEPTOR; COMPLEMENTARY RNA; COPPER ZINC SUPEROXIDE DISMUTASE; DOUBLE STRANDED RNA; LENTIVIRUS VECTOR; LIPOSOME; MESSENGER RNA; MICRORNA; PARVOVIRUS VECTOR; PLASMID VECTOR; PROTEIN SUBUNIT; RIBOZYME; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VIRUS VECTOR;

ALZHEIMER DISEASE; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSPORT; FELINE IMMUNODEFICIENCY VIRUS; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; GENE TARGETING; HUMAN; HUNTINGTON CHOREA; IMMUNE RESPONSE; NEUROLOGIC DISEASE; NONHUMAN; NONVIRAL GENE THERAPY; PATHOGENESIS; RNA ANALYSIS; RNA INTERFERENCE; RNA PROCESSING; RNA SEQUENCE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SPINOCEREBELLAR DEGENERATION; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOLOGICAL MODEL; DEGENERATIVE DISEASE; EVALUATION; GENE THERAPY; GENE TRANSFER; IMMUNOLOGY; INNATE IMMUNITY; PHYSIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALIA;

ANIMALS; GENE SILENCING; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNITY, NATURAL; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; RNA INTERFERENCE; SENSITIVITY AND SPECIFICITY;

EID: 34748875237     PISSN: 14739550     EISSN: 14774062     Source Type: Journal    
DOI: 10.1093/bfgp/elm005     Document Type: Article

References (84)

1. Denovan-wright EM, Davidson BZL. RNAi: A potential therapy for the dominantly inherited nucleotide repeat diseases. Gene Ther 2006; 13:525-31.
2. Dermaut B, Kumar-singh S, Kademakers R, et al. Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. Trends Genet 2005;21:664-72.
3. Bonini NM, La spada AR. Silencing polyglutamine degeneration with RNAi. Neuron 2005;48:715-8.
4. Filipowicz W. RNAi: The nuts and bolts of the RISC machine. Cell 2005;122:17-20.
5. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunla results in reversible co-suppression of homologous genes in trans. Plant Cell 1990;2:279-89.
6. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11.
7. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
8. Du T, Zamore PD. MicroPrimer: The biogenesis and function of microRNA. Development 2005;132:4645-52.
9. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 1999;13 3191-7.
10. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi, double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101: 25-33.
11. Rand T, Petersen S, Du F, Wang T. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 2005;123:621-9.
12. Hutvagner G. Small RNA asymmetry in RNAi: Function in RISC assembly and gene regulation. FEBSLetters 2005;579: 5850.
13. Song J-J, Smith SK, Hannon GJ, Joshua-tor L. Crystal structure of argonaute and its implications for RISC slicer activity. Science 2004;305:1434-7.
14. Liu J, Carmell MA, Rivas FV, et al. Argonaute2 Is the catalytic engine of mammalian RNAi. Science 2004;305: 1437-41.
15. Saxena S, Jonsson zo, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003; 278:44312-9.
16. Kim D, Villeneuve L, Morris K, Rossi J. Argonaute-1 directs siRNA mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol 2006;13:793-7.
17. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003;100: 9779-84.
18. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425: 415-9.
19. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: Stepwise processing and subcellular localization. Embo J 2002;21 4663-70.
20. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. Embo J 2004;23: 4051-60.
21. Pillai KS, Bhattacharyya SN, Artus CG, et al. Inhibition of translational initiation by Let-7 microRNA in human cells. Science 2005,309:1573-6.
22. Abdelgany A, Wood M, Beeson D. Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum Mol Genet 2003;12:2637-44.
23. Gocdert M. Tau gene mutations and their effects. Mov Disord 2005;20(Suppl 12).S45-52.
24. Miller VM, Xia H, Mairs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003;100: 7195-200.
25. Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer's disease genes with RNA interference: An efficient strategy for silencing mutant alleles. Nucleic Acids Res 2004;32:661-8.
26. Gonzalez-alegre P, Bode N, Davidson BL, Paulson HL. Silencing primary dystonia: Lentiviral-mediated RNA interference therapy for DYT1 clystonia. J Neurosci 2005;25: 10502-9.
27. Beckman JS, Estevez AG, Crow JP, Barbeito L. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci 2001;24(11 Suppl):S15-20.
28. Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11: 429-33.
29. Raoul C, Abbas-terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423-8.
30. Talbot K. Neuromuscular disorders: Therapeutic advances. Lancet Neurol 2007;6:18-9.
31. Xia XG, Zhou H, Zhou S, et al. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. J Neurochem 2005;92: 362-7.
32. Xia H, Mao Q, Paulson HL, Davidson BL. s1RNA-mediated gene silencing in vitro and in -vivo. Nat Biotechnol 2002;20:1006-10.
33. Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutannne-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004;10:816-20.
34. Forman MS, TrojanowskijQ, Lee VM. Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004;10: 1055-63.
35. Herard AS, Besret L, Dubois A, et al. siRNA targeted against amyloid precursor protein impairs synaptic activity in vivo. Neurobiol Aging 2006;27:1740-50.
36. Kao SC, Krichevsky AM, Kosik KS, Tsai LH. BACE1 suppression by RNA interference in primary cortical neurons. J Biol Chem 2004;279 1942-9.
37. Singer O, Marr RA, Rockenstein E, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005; 8:1343-9.
38. Isacson R, Kull B, Salmi P, Wahlestedt C. Lack of efficacy of 'naked' small interfering RNA applied directly to rat brain. Acta Physiol Scand 2003;179:173-7.
39. Thakker DR, Natt F, Husken D, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. PNAS 2004;101:17270-5.
40. Akaneya Y, Jiang B, Tsumoto T. RNAi-induced gene silencing by local electroporation in targeting brain region. J Neurophysiol 2005; 93:594-602.
41. Hassani Z, Lemkine GF, Erbacher P, et al. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med 2005;7: 198-207.
42. Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004;4:1103-13.
43. Zhang Y, Zhang YF, Bryant J, et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004;10:3667-77.
44. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441: 111-14.
45. Amarzguioui M, Brede G, Babaie E, et al. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes. Nucleic Acids Res 2000; 28:4113-24.
46. Czauderna F, Fechtner M, dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003;31: 2705-16.
47. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucl Acids Res 2003;31 589-95.
48. Hoshika S, Minakawa N, Kamiya H, Harashima H, Matsuda A. RNA interference induced by siRNAs modified with 4′-thioribonucleosides in cultured mammalian cells. AFEBS Lett 2005;579:3115-18.
49. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo and-HBV activity of chemically modified siRNAs. NatBiotechnol 2005;23:1002-7.
50. Morrissey DV, Blanchard K, Shaw L, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005;41: 1349-56.
51. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-8.
52. Whelan J. First clinical data on RNAi. Drug Discov Today 2005; 10:1014-15.
53. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of iRNAs reduces 'off-target' transcript silencing. RNA 2006;12:1197-205.
54. Rumi M, Ishihara S, Aziz M, et al. RNA polymerase II mediated transcription from the polymerase III promoters in short hairpin RNA expression vector. Biochem Biophys Res Commun 2006;339 540-47.
55. Lambeth LS, Moore RJ, Muralitharan M, et al. Characterisation and application of a bovine U6 promoter for expression of short hairpin RNAs. BMC Biotechnol 2005; 5:13.
56. Wakiyama M, Matsumoto T, Yokoyama S. Drosophila U6 promoter-driven short hairpin KNAs effectively induce RNA interference in Schneider 2 cells. Biochem Biophys Res Commun 2005;331:1163-70.
57. Lin X, Yang J, Chen J, et al. Development of a tightly regulated U6 promoter for shRNA expression. FEBS Lett 2004;577:376-80.
58. Spankuch B, Matthess Y, Knecht R, et al. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004;96:862-72.
59. Chang K, Elledge SJ, Hannon GJ. Lessons from Nature: MicroRNA-based shRNA libraries. Nat Methods 2006;3: 707-14.
60. Karpala AJ, Doran TJ, Bean AGD. Immune responses to dsRNA: Implications for gene silencing technologies. Immunology and Cell Biology 2005;83:211-16.
61. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21:635-37.
62. Persengiev SP, Zhu X, Green MR. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs siRNAs). RNA 2004;10:12-18.
63. Lin X, Ruan X, Anderson MG, et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucl Acids Res 2005;33:4527-35.
64. Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA 2006;12: 1179-87.
65. Scacheri PC, Rozenblatt-rosen O, Caplen NJ, et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 2004;101: 1892-97.
66. Yamada T, Morishita S. Accelerated off-target search algorithm for siRNA. Bioinformatics 2005;21:1316-24.
67. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26:199-213.
68. Hornung V, Guenthner-biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11 263-70.
69. Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23: 457-62.
70. Kariko K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004;172:6545-9.
71. Sledz CA, Holko M, De veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9.
72. Sioud M, Sorensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 2003;312:1220-5.
73. Jackson AL, Linsley PS. Noise amidst the silence: Off-targqt effects of siRNAs?. Trends Genet 2004;20:521-4.
74. Kariko K, Bhuyan P, Capodici J, et al. Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs 2004; 177:132-8.
75. Judge AD, Bola G, Lee AC, Maclachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006;13:494-505.
76. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
77. Giraldez AJ, Cinalli RM, Glasner ME, et al. MicroRNAs regulate brain morphogenesis in zebrafish. Science 2005;308: 833-8.
78. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432:226-30.
79. Kim J, Krichevsky A, Grad Y, et al. Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci USA 2004;101: 360-5.
80. Schratt GM, Tuebing F, Nigh. EA, et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006;439:283-9.
81. Koller E, Propp S, Murray H, et al. Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res 2006;34:4467-76.
82. Grimm D, Streetz K, Jopling C, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-41.
83. Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet 2003;35:215-7.
84. Carthew RW. RNA interference: The fragile X syndrome connection. Curr Biol 2002;12:R852-4.